abstract |
The present invention discloses methods for treating autoimmune and inflammatory diseases using CD37 agents (including, but not limited to, CD37 binding antibodies and immunoconjugates) to deplete B cells (eg, noncancerous B cells). The present invention further discloses the sequences of the light chain variable region and the heavy chain variable region of an antibody that specifically binds to CD37. |